About this ETF
The index is a rules-based index that tracks the performance of a portfolio of companies conducting legal activities under the national laws of the applicable country related to medical psychedelics, medical cannabis, cannabis pharmaceuticals and cannabidiol derivatives, and ketamine. The fund uses a “replication” strategy to achieve its investment objective, it will invest in all of the component securities of the index in the same approximate proportions as in the index. It is non-diversified.
Description from the fund data provider · profile as of Aug 27, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +4.52% | +6.96% | -34.30% | -50.08% | -72.04% | — | — | -6.31% | -7.06% |
| Total return | +4.42% | +6.88% | -34.30% | -50.08% | -71.28% | — | — | -6.06% | -6.93% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Sep 01, 2022. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.75% | Annual cost of a $10,000 investment | $75.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Apr 17, 2023 — portfolio reporting date from the data provider; holdings are not live positions. 2 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Cash & Other | — | 100.00% | 5.04M | $5.0M |
| 2 | ALT HOUSE CANNABIS INC | 1914272D.TO | 0.00% | 10.69K | $0.00 |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Irregular | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 29, 2021 | Last payment | $0.3330 (Dec 31, 2021) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 29, 2021 | Dec 30, 2021 | Dec 31, 2021 | $0.3330 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
Liquidity
| Volume today | 20.62K | Average volume | 7.15K |
| AUM | $4.7M | Premium/Discount | -0.51% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for PSY
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.
PSY